IRF1-IN-2

IRF1-IN-2 (Compound I-19) is an IRF1 inhibitor. IRF1-IN-2 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-2 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1; inhibits the Pho of TKB1, upregulates GPX4 and downregulates FACL4) . IRF1-IN-2 has a protective effect on ionizing radiation-induced inflammatory skin injury[1].

Product Specifications

CAS Number

[708245-32-3]

UNSPSC

12352005

Target

Caspase; Glutathione Peroxidase; IFNAR; Interleukin Related; PARP; Pyroptosis

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/irf1-in-2.html

Purity

99.83

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(S(=O)(N2CCCC2)=O)C=C1)C3=CC=CC=C3OC

Molecular Formula

C18H20N2O4S

Molecular Weight

360.43

References & Citations

[1]Geng, et al. Chaperone- and PTM-mediated activation of IRF1 tames radiation-induced cell death and the inflammatory response. Cell Mol Immunol. 2024 Aug;21 (8) :856-872.